Company registration number 15689618 (England and Wales)
RE-AIM THERAPEUTICS LTD
FINANCIAL STATEMENTS
FOR THE PERIOD FROM 1 MAY 2025 TO 31 MARCH 2026
PAGES FOR FILING WITH REGISTRAR
RE-AIM THERAPEUTICS LTD
CONTENTS
Page
Statement of financial position
1
Notes to the financial statements
2 - 9
RE-AIM THERAPEUTICS LTD
STATEMENT OF FINANCIAL POSITION
AS AT
31 MARCH 2026
31 March 2026
- 1 -
2026
2025
Notes
£
£
£
£
Fixed assets
Tangible assets
6
64,719
2,369
Current assets
Debtors
7
311,635
33,939
Cash and cash equivalents
5,122,556
28,292
5,434,191
62,231
Creditors: amounts falling due within one year
8
(166,356)
(78,661)
Net current assets/(liabilities)
5,267,835
(16,430)
Net assets/(liabilities)
5,332,554
(14,061)
Capital and reserves
Called up share capital
10
-
0
-
0
Share premium account
7,347,480
347,500
Share-based payment reserve
4,154
-
0
Profit and loss reserves
(2,019,080)
(361,561)
Shareholders' funds
5,332,554
(14,061)

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with section 444 of the Companies Act 2006, all of the members of the company have consented to the preparation of abridged financial statements pursuant to paragraph 1A of Schedule 1 to the Small Companies and Groups (Accounts and Directors’ Report) Regulations (SI 2008/409)(b).

The directors of the company have elected not to include a copy of the income statement within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 22 July 2026 and are signed on its behalf by:
R Bulthuis
Director
Date: 22/07/2026
Company registration number 15689618 (England and Wales)
The notes on page 2 to 9  form part of these financial statements.
RE-AIM THERAPEUTICS LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 MARCH 2026
- 2 -
1
Accounting policies
Company information

Re-Aim Therapeutics Ltd is a private company limited by shares incorporated in England and Wales, registered number 15689618. The registered office is Innovation Building, Old Campus Road, Roosevelt Drive, Oxford, England, OX3 7FZ.

1.1
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

At the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statementstrue.

1.3
Tangible fixed assets and depreciation

Property, plant and equipment are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Plant and equipment
25% straight line
Office equipment
33% straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.4
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

 

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

RE-AIM THERAPEUTICS LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 31 MARCH 2026
1
Accounting policies
(Continued)
- 3 -

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

1.5
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.6
Financial instruments
The company has applied sections 11 and 12 of FRS 102. The company entered into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors and certain preference shares.
An equity instrument is defined as any contract that evidences a residual interest in an entity's assets after deducting all of its liabilities.
1.7
Foreign currencies
Foreign currency transactions are initially recorded in the functional currency, by applying the spot exchange rate as at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated at the exchange rate ruling at the reporting date, with any gains or losses being taken to the profit and loss account.
1.8
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

RE-AIM THERAPEUTICS LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 31 MARCH 2026
1
Accounting policies
(Continued)
- 4 -
1.9
Pensions

Contributions to defined contribution plans are recognised as an expense in the period in which the related service is provided.

 

Prepaid contributions are recognised as an asset to the extent that the prepayment will lead to a reduction in future payments or a cash refund.

 

When contributions are not expected to be settled wholly within 12 months of the end of the reporting date in which the employees render the related service, the liability is measured on a discounted present value basis. The unwinding of the discount is recognised as a finance cost in profit or loss in the period in which it arises.

1.10
Research and development expenditure

Research expenditure is written off in the period in which it is incurred.

 

Development expenditure incurred is capitalised as an intangible asset only when all of the following criteria are met:

 

- It is technically feasible to complete the intangible asset so that it will be available for use or sale;

- There is the intention to complete the intangible asset and use or sell it;

- There is the ability to use or sell the intangible asset;

- The use or sale of the intangible asset will generate probable future economic benefits;

- There are adequate technical, financial and other resources available to complete the development and to use or sell the intangible asset; and

- The expenditure attributable to the intangible asset during its development can be measured reliably.

 

Expenditure that does not meet the above criteria is expensed as incurred.

1.11
Share-based payments
Equity-settled share-based payment transactions are measured at fair value at the date of grant. The fair value is expensed on a straight-line basis over the vesting period, with a corresponding increase in equity. This is based upon the company's estimate of the shares or share options that will eventually vest which takes into account all vesting conditions and non-market performance conditions, with adjustments being made where new information indicates the number of shares or share options expected to vest differs from previous estimates.
Fair value is determined using an appropriate pricing model. All market conditions and non-vesting conditions are taken into account when estimating the fair value of the shares or share options. As long as all other vesting conditions are satisfied, no adjustment is made irrespective of whether market or non-vesting conditions are met.
Where the terms of an equity-settled transaction are modified, an expense is recognised as if the terms had not been modified. In addition, an expense is recognised for any increase in the fair value of the transaction, as measured at the date of modification.
Where an equity-settled transaction is cancelled or settled, it is treated as if it had vested on the date of cancellation or settlement, and any expense not yet recognised in profit or loss is expensed immediately.
1.12
Government grants and R&D expenditure credits
Government grants, including research and development tax credits under the UK R&D regime, are recognised where there is reasonable assurance that the grant will be received and that all related conditions will be complied with.
RE-AIM THERAPEUTICS LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 31 MARCH 2026
1
Accounting policies
(Continued)
- 5 -
Such credits are recognised in the profit and loss account on a systematic basis over the periods in which the related research and development expenditure is recognised as an expense. The credit is presented within other operating income.
2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Key sources of estimation uncertainty

The estimates and assumptions which have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities are as follows.

Depreciation and useful lives of property, plant and equipment:
The company reviews the estimated useful lives of assets annually, based on expected usage and technological development.
Share based payments:
The principal assumptions used in determining the fair value of the ordinary shares included:
- Capital structure and rights of the Company's share classes, including Series Seed liquidation preferences
- Probability‑weighted exit scenarios and expected time to liquidity
- Expected equity and asset volatility, derived from comparable early‑stage life sciences companies
- Risk‑free interest rates, based on government bond yields at the valuation date
- Discount for lack of marketability, reflecting the absence of a public market for the Company's shares
3
Operating loss
2026
2025
Operating loss for the period is stated after charging:
£
£
Depreciation of tangible fixed assets
8,765
624
4
Auditor's remuneration
2026
2025
£
£
Audit of the financial statements of the company
10,300
-
0
RE-AIM THERAPEUTICS LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 31 MARCH 2026
- 6 -
5
Employees

The average monthly number of persons (including directors) employed by the company during the period was:

2026
2025
Number
Number
Total
3
1
6
Tangible assets
Plant and machinery
Office equipment
Total
£
£
£
Cost
At 1 May 2025
2,993
-
0
2,993
Additions
65,940
5,174
71,114
At 31 March 2026
68,934
5,174
74,108
Depreciation
At 1 May 2025
624
-
0
624
Depreciation charged in the period
8,033
732
8,765
At 31 March 2026
8,656
732
9,388
Net book value
At 31 March 2026
60,277
4,442
64,719
At 30 April 2025
2,369
-
0
2,369
7
Debtors
2026
2025
Amounts falling due within one year:
£
£
Other debtors
15,645
-
R&D tax credit debtor
135,420
27,363
Prepayments and accrued income
64,415
-
0
VAT debtor
96,155
6,576
311,635
33,939
RE-AIM THERAPEUTICS LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 31 MARCH 2026
- 7 -
8
Creditors: amounts falling due within one year
2026
2025
£
£
Trade creditors
50,265
47,644
Taxation and social security
46,047
4,354
Wages payable
-
0
26,663
Accruals
70,044
-
166,356
78,661
9
Deferred taxation
As at 31 March 2026 there existed a potential net deferred tax asset of £412,333 comprising an asset of £31,765  in respect of the RDEC restriction, and asset of £396,748 in respect of unrelieved trading losses and a liability of £16,180 in respect of accelerated capital allowances. This has not been reflected as an asset given the uncertainty of future revenue streams and as the company is committed to significant continued investment in research and development. No current tax has been recognised due to losses incurred in the period.
10
Share capital
2026
2025
£
£
Allotted, called up and fully paid
113,900 (2025: 113,900) Ordinary Shares of £0.000001 each
0.11
0.11
-
-
Allotted, called up and fully paid
215,384 (2025: NIL) Series Seed Shares of £0.000001 each
0.22
-
-
0
-
0
215,384 Series Seed shares of £0.000001 each were issued at a subscription price of £32.50 per share, raising total proceeds of £7 million.
The Company has two classes of share in issue: ordinary shares and Series Seed shares. The ordinary shares have full voting rights and rank pari passu for dividends and distributions on a return of capital after payment of an aggregate of £0.01 to the holders of any deferred shares and after payment to the holders of the Series Seed shares. The Series Seed shares carry full voting rights and full rights to dividends and to distributions on a return of capital after payment of an aggregate of £0.01 to the holders of any deferred shares. They rank ahead of the ordinary shares for dividends and capital distributions.Neither class of share is redeemable. No conversion rights or additional preferential rights are attached to the Series Seed shares beyond those disclosed above.
11
Audit report information

As the income statement has been omitted from the filing copy of the financial statements, the following information in relation to the audit report on the statutory financial statements is provided in accordance with s444(5B) of the Companies Act 2006.

The auditor's report is unqualified and includes the following:

RE-AIM THERAPEUTICS LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 31 MARCH 2026
11
Audit report information
(Continued)
- 8 -
Opinion

In our opinion:

Senior Statutory Auditor:
Stephen Wyborn
Statutory Auditor:
Grant Thornton UK LLP
Date of audit report:
22 July 2026
12
Related party transactions
The following transactions were carried out with related parties:
Transactions with directors
In July 2025, Dr A Maroof, a director of the company, advanced a short-term loan of £25,000 to the company. The loan was interest-free, unsecured and repayable on demand. The loan was fully repaid in October 2025 and no balance was outstanding at the reporting date.
During the year, the company was charged £3,625 (2025: £nil) for consultancy services provided by D Patel, a director of the company, outside of their role as a director. No amounts were outstanding at the reporting date.
Transactions with shareholders
During the year, the company was charged £18,000 (2025: £nil) by Oxford Science Enterprises plc, a shareholder, for recharged legal costs. In addition, £15,000 (2025: £nil) was charged for directors' services provided by Dr J C Fox, a director of the company, via the shareholder. No amounts were outstanding at the reporting date. £7,500 (2025: £nil) was included in prepayments at 31 March 2026.
During the year, the company was charged £259,768 (2025: £nil) by Syncona Portfolio Limited, a shareholder. This included amounts in respect of directors' services provided by directors R Bulthuis, P L Joffrin and Dr J Tsai. No amounts were outstanding at the reporting date. £2,500 (2025: £nil) was included in accruals at 31 March 2026.
Transactions with other related parties
During the year, the company paid £3,000 (2025: £nil) to a close family member of a director in respect of accountancy services. No amounts were outstanding at the reporting date.
RE-AIM THERAPEUTICS LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 31 MARCH 2026
- 9 -
13
Ultimate controlling party
The directors consider Syncona Portfolio Limited to be the Company's ultimate controlling party. Syncona Portfolio Limited holds approximately 42% of the Company's issued share capital and, through the rights attaching to its shareholding and other contractual arrangements, has the ability to exercise control over the Company. In particular, it is entitled to the greater part of the assets available for distribution on a winding up.
14
Share-based payments
The Company operates equity‑settled share option arrangements for certain employees, consultants and directors. The options granted give the holder the right to acquire ordinary shares in the Company at a nominal exercise price and are subject to service‑based vesting conditions.
In accordance with FRS 102 Section 26 – Share‑based Payments, the fair value of options granted is measured at the grant date and recognised as an expense over the vesting period, with a corresponding credit to equity.
Valuation of share options
The fair value of the share options granted has been determined by reference to the fair value of the Company's ordinary shares at the grant date, as assessed by an independent third‑party valuation.
The independent valuation was prepared using a Hybrid Option Pricing Model, incorporating both:
- a Current Value Method, and
- an Option Pricing Method to reflect the Company's capital structure, liquidation preferences and the uncertain timing of exit.
The concluded fair value of an ordinary share at the valuation date was £2.59 per share.
As at 31 March 2026 the Company had issued 17,379 Share Options (2025: NIL) to its employees and consultants of which 1,604 had vested (2025: NIL). The exercise price was £32.50 and the vesting period was 48 months.
The number of options expected to vest is reviewed at each reporting date, and the cumulative expense recognised is adjusted accordingly. Where employees leave the Company, vesting is restricted to the number of options contractually vested at the date of leaving.
The share‑based payment charge recognised in the profit and loss account for the year ended 31 March 2026 was £4,154 (2025: £nil). As at 31 March 2026, the cumulative amount recognised in equity in respect of share‑based payment arrangements was £4,154 (2025: £nil).
2026-03-312025-05-01falsefalsefalse22 July 2026CCH SoftwareCCH Accounts Production 2026.100No description of principal activityDr Asher MaroofJason GoldsteinMr Roel BulthuisDr Justian Craig FoxMr Pierre-Louis Emmanuel JoffrinJohn TsaiDr Dhavalkumar Patel156896182025-05-012026-03-31156896182026-03-31156896182025-04-3015689618core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipment2025-04-3015689618core:CurrentFinancialInstrumentscore:WithinOneYear2026-03-3115689618core:CurrentFinancialInstrumentscore:WithinOneYear2025-04-3015689618core:CurrentFinancialInstruments2026-03-3115689618core:ShareCapital2026-03-3115689618core:ShareCapital2025-04-3015689618core:SharePremium2026-03-3115689618core:SharePremium2025-04-3015689618core:OtherReservesSubtotal2026-03-3115689618core:OtherReservesSubtotal2025-04-3015689618core:RetainedEarningsAccumulatedLosses2026-03-3115689618core:RetainedEarningsAccumulatedLosses2025-04-3015689618core:ShareCapitalOrdinaryShares2026-03-3115689618core:ShareCapitalOrdinaryShares2025-04-3015689618bus:Director32025-05-012026-03-31156896182024-04-292025-04-3015689618core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipment2025-04-3015689618core:ComputerEquipment2026-03-3115689618core:ComputerEquipment2025-05-012026-03-3115689618core:ComputerEquipment2025-04-3015689618core:CurrentFinancialInstruments2025-04-3015689618core:CurrentFinancialInstruments12026-03-3115689618bus:PrivateLimitedCompanyLtd2025-05-012026-03-3115689618bus:SmallCompaniesRegimeForAccounts2025-05-012026-03-3115689618bus:FRS1022025-05-012026-03-3115689618bus:Audited2025-05-012026-03-3115689618bus:Director12025-05-012026-03-3115689618bus:Director22025-05-012026-03-3115689618bus:Director42025-05-012026-03-3115689618bus:Director52025-05-012026-03-3115689618bus:Director62025-05-012026-03-3115689618bus:Director72025-05-012026-03-3115689618bus:FullAccounts2025-05-012026-03-31xbrli:purexbrli:sharesiso4217:GBP